Roquefort Therapeutics Acquires Cancer Treatment in Strategic £32 Million Deal

A small biotech company, Roquefort Therapeutics, is set to enhance its portfolio through the acquisition of rights to a clinical-stage cancer treatment in a reverse takeover valued at £32 million. This transaction will enable Roquefort to transition from its main listing on the London Stock Exchange to the Alternative Investment Market, which is known for being less regulated.

The acquisition involves a cash-and-shares deal, where Roquefort will gain worldwide rights to AO-252, an orally administered small molecule currently in phase I trials in the United States. Promising early results indicate it may serve as a less toxic alternative to conventional cancer treatments such as chemotherapy.

As part of the deal, Roquefort plans to raise £8.5 million via a share placing, which will facilitate further development of its clinical programmes. The company aims to accelerate development, with dose expansion studies expected to commence shortly and an increased focus on patient recruitment.

Leadership changes are anticipated, with Sotirios Stergiopoulos, co-founder of Coiled Therapeutics in the United States, slated to become chairman of the enlarged Aim-quoted company. He is expected to participate in the fundraising round alongside other executives.

Roquefort’s executive chairman, Stephen West, will transition to a non-executive director position. The recent acquisition of Halda Therapeutics by Johnson & Johnson for $3.1 billion reinforces the growing appetite in the market for clinical-stage cancer therapies.

Industry observers note that Roquefort’s entry into this arena may generate substantial data readouts by the fourth quarter of this year. This could drive shareholder value and offer significant opportunities for strategic partnerships.